In a major settlement, Made-in-China.com will stop selling research chemicals to U.S. buyers following an investigation by Connecticut’s Attorney General.
The FDA proposed restricting three GLP-1 drugs from the 503B bulks list, which would prevent outsourcing facilities from compounding them from raw ingredients without a clear clinical need.
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
The former doctor admitted to buying tirzepatide from a lab in China and distributing it without medical evaluations, and is now being sued by a former hospital employee who alleges the drug caused life-threatening complications requiring major surgery.
What do FDA records of GLP-1 and antibiotic imports show about freight fraud patterns over the last six months?
In March, customs officers in Cincinnati announced the seizure of thousands of shipments of GLP-1s and other peptides packaged inside more than 300 “master cartons” with deceptive manifests meant to slip into the country unnoticed. Curious how this smuggling scheme works? Read on.
The Jardiance upper payment limit, based on the Medicare maximum fair price, is set to take effect in 2027.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
A recent FDA warning letter highlights upstream supply chain vulnerabilities.
Troubling practices alleged at a compounding pharmacy that supplied glp-1s. Learn more.
Congressman Krishnamoorthy is looking into GLP-1 drugs that may be entering the US unlawfully.
Click the images below to see more recent videos.